Ultragenyx Pharmaceutical (RARE) Insider Trading & Ownership $38.69 -0.67 (-1.70%) As of 04:00 PM Eastern Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Ultragenyx Pharmaceutical (NASDAQ:RARE) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage5.80%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)8Amount OfInsider Selling(Last 12 Months)$9.23 M Get RARE Insider Trade Alerts Want to know when executives and insiders are buying or selling Ultragenyx Pharmaceutical stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address RARE Insider Buying and Selling by Quarter Remove Ads Ultragenyx Pharmaceutical Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails3/6/2025Howard HornCFOSell1,785$40.40$72,114.00 3/3/2025Emil D KakkisCEOSell73,434$42.10$3,091,571.40 3/3/2025John Richard PinionInsiderSell14,439$42.10$607,881.90 3/3/2025Theodore Alan HuizengaCAOSell967$42.10$40,710.70 3/3/2025Thomas Richard KassbergEVPSell6,028$42.10$253,778.80 2/28/2025Emil D KakkisCEOSell25,000$42.48$1,062,000.00 2/27/2025Karah Herdman ParschauerEVPSell2,990$42.88$128,211.20 12/30/2024Emil D KakkisCEOSell11,727$42.23$495,231.21 12/10/2024Emil D KakkisCEOSell8,273$50.00$413,650.00 10/10/2024Howard HornCFOSell7,465$52.76$393,853.40 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 9/3/2024Emil D KakkisCEOSell20,000$55.85$1,117,000.00 9/3/2024Theodore Alan HuizengaCAOSell91$56.19$5,113.29 8/6/2024Emil D KakkisCEOSell20,000$50.17$1,003,400.00 7/2/2024Corazon (Corsee) D SandersDirectorSell584$40.98$23,932.32 6/12/2024Karah Herdman ParschauerEVPSell9,806$45.00$441,270.00 6/10/2024Corazon (Corsee) D SandersDirectorSell1,737$41.10$71,390.70 4/18/2024Eric CrombezEVPSell142$44.10$6,262.20 (Data available from 1/1/2013 forward) RARE Insider Trading Activity - Frequently Asked Questions Who is on Ultragenyx Pharmaceutical's Insider Roster? The list of insiders at Ultragenyx Pharmaceutical includes Camille L Bedrosian, Corazon (Corsee) D Sanders, Dennis Karl Huang, Emil D Kakkis, Eric Crombez, Erik Harris, Howard Horn, John Richard Pinion, Karah Herdman Parschauer, Mardi Dier, Matthew K Fust, Theodore Alan Huizenga, and Thomas Richard Kassberg. Learn more on insiders at RARE. What percentage of Ultragenyx Pharmaceutical stock is owned by insiders? 5.80% of Ultragenyx Pharmaceutical stock is owned by insiders. Learn more on RARE's insider holdings. Which Ultragenyx Pharmaceutical insiders have been selling company stock? The following insiders have sold RARE shares in the last 24 months: Corazon (Corsee) D Sanders ($199,377.87), Emil D Kakkis ($8,786,885.17), Eric Crombez ($6,262.20), Erik Harris ($242,461.00), Howard Horn ($465,967.40), John Richard Pinion ($932,822.38), Karah Herdman Parschauer ($968,413.76), Matthew K Fust ($620,481.60), Theodore Alan Huizenga ($188,442.05), and Thomas Richard Kassberg ($2,135,624.01). How much insider selling is happening at Ultragenyx Pharmaceutical? Insiders have sold a total of 342,071 Ultragenyx Pharmaceutical shares in the last 24 months for a total of $14,546,737.44 sold. Ultragenyx Pharmaceutical Key ExecutivesDr. Emil D. Kakkis M.D. (Age 64)Ph.D., Founder, President, CEO & Director Compensation: $1.46MMr. Howard Horn (Age 46)Executive VP of Corporate Strategy & CFO Compensation: $184.81k2 recent tradesMs. Karah Herdman Parschauer J.D. (Age 46)Chief Legal Officer & Executive VP of Corporate Affairs Compensation: $846.74k1 recent tradesMr. John Richard Pinion II (Age 58)Chief Quality Operations Officer & Executive VP of Translational Sciences Compensation: $860.05k1 recent tradesMr. Erik Harris (Age 53)Executive VP & Chief Commercial Officer Compensation: $878.77kMr. Theodore A. Huizenga (Age 53)Senior VP, Corporate Controller & Principal Accounting Officer 1 recent tradesMr. Ernie W. Meyer (Age 59)Chief Human Resources Officer & Executive VP Mr. Thomas R. Kassberg (Age 64)Chief Business Officer & Executive VP Compensation: $714.84kMr. Vimal Srivastava (Age 59)Senior Vice President of Business Development & Alliance Management Mr. Dennis Karl Huang (Age 59)Chief Technical Operations Officer and EVP of Gene Therapy Research & Development Compensation: $331.33k More Insider Trading Tools from MarketBeat Related Companies ITCI Insider Transactions GMAB Insider Transactions MRNA Insider Transactions VTRS Insider Transactions SRPT Insider Transactions PCVX Insider Transactions ROIV Insider Transactions RVMD Insider Transactions LNTH Insider Transactions TGTX Insider Transactions Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles NVIDIA Insiders Sell: This Is What It Means for the Market Top 3 Insider Stock Buys in March—Are They Still Good in April?Grocery Outlet Insider and Institutional Buyers Signal BottomSentinelOne Insider Selling? Why Investors Should Stay Bullish 3 Companies Buying Back Stock—Why It Matters This page (NASDAQ:RARE) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ultragenyx Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ultragenyx Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
